Drug news

Zerbaxa (ceftolozane + tazobactam) is launched in the UK-Merck Inc.

Read time: 1 mins

Last updated:24th Nov 2015

Published:24th Nov 2015

Source: Pharmawand

Zerbaxa (ceftolozane + tazobactam) from Merck Inc. is launched in the United Kingdom to treat complicated intra-abdominal infections, acute pyelonephritis and complicated urinary tract infections.

Comment: The combination was approved in the US in December 2014 and was EU approved in September 2015.The drug was originally developed by Cubist Pharma which was acquired by Merck Inc.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

FDA approves Fabhalta (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH

Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH])

2 mins

Drug news

Merck KGaA provides update on phase III results for evobrutinib in relapsing multiple sclerosis

Merck KGaA, a leading science and technology company, announced that its two Phase III EVOLUTION clinical trials (evolution RMS 1 and evolution RMS 2) investigating the efficacy and safety of evobrutinib did not meet their primary endpoints of reducing annualized relapse rates (ARR) in people with relapsing multiple sclerosis (RMS) compared to oral teriflunomide (Aubagio) (0.11 vs. 0.11 in evolution RMS 1 and 0.15 for evobrutinib vs. 0.14 for teriflunomide in evolution RMS 2, p=NS in both trials)

1 min

Drug news

Data presentations for lumateperone and preclinical ITI 1549 at the American College of Neuropsychopharmacology Annual Meeting

Intra-Cellular Therapies, Inc. announced data presentations at the American College of Neuropsychopharmacology (ACNP) 62nd Annual Meeting

3 min

See all news